This page shows the publications co-authored by Lynda Schneider and Rima Rachid.
Yee CSK, El Khoury K, Albuhairi S, Broyles A, Schneider L, Rachid R. Reply. J Allergy Clin Immunol Pract. 2019 04; 7(4):1376-1377.
Yee CSK, El Khoury K, Albuhairi S, Broyles A, Schneider L, Rachid R. Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017). J Allergy Clin Immunol Pract. 2019 03; 7(3):1024-1031.e3.
Yee CSK, Albuhairi S, Noh E, El-Khoury K, Rezaei S, Abdel-Gadir A, Umetsu DT, Burke-Roberts E, LeBovidge J, Schneider L, Rachid R. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. J Allergy Clin Immunol Pract. 2019 02; 7(2):451-461.e7.
Albuhairi S, El Khoury K, Yee C, Schneider L, Rachid R. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018. Ann Allergy Asthma Immunol. 2018 12; 121(6):722-728.e1.
Albuhairi S, Sare T, Lakin P, El Khoury K, Crestani E, Schneider LC, Anzaldi R, Patterson A, Rachid R. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment. J Allergy Clin Immunol Pract. 2018 Sep - Oct; 6(5):1711-1716.e4.
MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, Heimall J, Makhija M, Robison R, Chinthrajah RS, Lee J, Lebovidge J, Dominguez T, Rooney C, Lewis MO, Koss J, Burke-Roberts E, Chin K, Logvinenko T, Pongracic JA, Umetsu DT, Spergel J, Nadeau KC, Schneider LC. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8.
Umetsu DT, Rachid R, Schneider LC. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015; 8(1):20.
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013 Dec; 132(6):1368-74.
Rachid R, Leslie D, Schneider L, Twarog F. Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. J Allergy Clin Immunol. 2011 Feb; 127(2):524-8.
Stranks AJ, Minnicozzi SC, Miller SJ, Burton OT, Logsdon SL, Spergel JM, Nadeau KC, Pongracic JA, Umetsu DT, Rachid R, MacGinnitie AJ, Schneider LC, Oettgen HC. Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies. Ann Allergy Asthma Immunol. 2019 02; 122(2):213-215.
Abdel-Gadir A, Schneider L, Casini A, Charbonnier LM, Little SV, Harrington T, Umetsu DT, Rachid R, Chatila TA. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018 07; 48(7):825-836.
Burton OT, Logsdon SL, Zhou JS, Medina-Tamayo J, Abdel-Gadir A, Noval Rivas M, Koleoglou KJ, Chatila TA, Schneider LC, Rachid R, Umetsu DT, Oettgen HC. Oral immunotherapy induces IgG antibodies that act through Fc?RIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014 Dec; 134(6):1310-1317.e6.
Castigli E, Wilson S, Garibyan L, Rachid R, Bonilla F, Schneider L, Morra M, Curran J, Geha R. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007 Apr; 39(4):430-1.
Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005 Aug; 37(8):829-34.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.